MS Patient Requesting Unproven Treatment

Clinical Scenario

Janet Morrison, 45, books a face-to-face appointment about new medication for her MS. She was diagnosed with relapsing-remitting MS 8 years ago, now secondary progressive. Previous treatments (interferon beta, glatiramer acetate, natalizumab) had limited effectiveness. She recently saw a social media video about a treatment (possibly stem cell therapy or a dietary supplement) claiming dramatic improvements in MS patients and is asking her GP to prescribe or arrange it. She is frightened about her future independence and feels desperate for something that works.

What This Case Tests

Addressing health misinformation from social media compassionately; understanding the difference between evidence-based and unproven treatments; acknowledging hope and desperation without feeding false hope; maintaining the therapeutic relationship when declining a request; signposting to legitimate MS support and clinical trials.

Common Mistakes Trainees Make

The three most common mistakes are: dismissing the treatment without understanding why Janet is drawn to it (her desperation and fear of losing independence are the real drivers), agreeing to prescribe or investigate an unproven treatment to maintain the relationship (this is not compassionate — it is harmful), and failing to offer any constructive alternative — Janet needs something to hope for, and legitimate options may exist (clinical trials, MS Society resources, specialist review for newer DMTs).

The Consultation Challenge

Janet is frightened. Her MS has transitioned from relapsing-remitting to secondary progressive, which means the trajectory is worsening. Previous treatments have not worked well. She has seen a compelling social media video showing someone with MS experiencing dramatic improvement, and she wants that for herself. This is not naivety — it is desperation.

Start by understanding what she has seen and why it resonated. "Can you tell me about what you saw? What specifically made you think this could help?" This validates her active engagement with her health and gives you the information to address the specific claims.

Assess the treatment critically but without condescension. Many viral MS treatments fall into categories: stem cell therapies (HSCT has genuine evidence for relapsing MS but is not available through GP prescribing and carries significant risks), dietary supplements (often marketed aggressively with anecdotal testimonials but no RCT evidence), and off-label drug repurposing (some with emerging evidence, most without). The specific treatment will guide your discussion.

Acknowledge the emotional reality: "I can completely understand why you'd be excited about this. Living with progressive MS and watching treatments not work as hoped must be incredibly frightening. When someone offers hope, it's natural to want to believe it." This validates her feelings without endorsing the treatment.

Then be honest about the evidence — or lack of it. Social media testimonials are not evidence. Dramatic improvement videos may be staged, selectively edited, or represent placebo responses. Clinical trials exist for a reason: to distinguish treatments that work from those that don't, and to identify harms. Unproven treatments can cause physical harm, financial exploitation, and the psychological damage of false hope followed by disappointment.

Offer constructive alternatives: specialist neurology review (are there newer disease-modifying therapies she hasn't tried?), MS Society resources (evidence-based information, peer support, quality of life advice), clinical trial registries (she may be eligible for genuine trials), and psychological support for adjusting to progressive MS.

Time check: Spend the first 4 minutes understanding what Janet has seen and why it appeals to her. By minute 7, address the evidence gap compassionately. Use minutes 8-10 for constructive alternatives. Reserve the final 2 minutes for emotional support and follow-up.

How Examiners Mark This Case

Data Gathering and Diagnosis: Examiners assess whether you explore what treatment Janet is requesting (specifics matter for evidence discussion), understand her current MS status and treatment history, assess her emotional state and functional concerns, and explore what is driving the request (fear of losing independence, desperation after failed treatments). They look for empathy-driven questioning, not interrogation.

Clinical Management and Medical Complexity: Examiners expect you to explain why unproven treatments cannot be prescribed (lack of evidence, potential harms, GMC responsibilities), demonstrate knowledge of the limitations of current treatments for secondary progressive MS, and offer constructive alternatives (specialist review, clinical trials, MS Society). A trainee who dismisses the request without offering alternatives, or who agrees to prescribe to maintain rapport, will score poorly.

Relating to Others: The critical domain. Examiners assess whether you acknowledge Janet's fear and desperation, validate her hope without feeding it falsely, decline the request compassionately, and ensure Janet leaves feeling heard and supported rather than dismissed. The consultation should feel like a partnership — you and Janet facing her MS together — not a gatekeeper refusing entry.

Example Opening

Strong opening: "Hello Janet, I can see you've been looking into something new for your MS. I'd really like to hear about what you've found — can you tell me what you saw and what made you think it could help?"

When addressing the evidence gap: "I can see why that video was so compelling — the results looked amazing. But here's my concern: social media testimonials aren't the same as clinical evidence. In medicine, we've learned the hard way that treatments can look miraculous in individual stories but turn out to be ineffective or even harmful when tested properly. I don't want you to go through the disappointment of investing hope and money in something that doesn't deliver."

Avoid: "That sounds like quackery — you shouldn't believe everything you see on social media." (Dismissive and patronising).

How This Appears in the SCA

Patients requesting unproven treatments test your ability to maintain the therapeutic relationship while being honest about evidence. This case combines chronic disease management, misinformation handling, and emotional support for a patient facing progressive disability. Examiners value compassion combined with clinical integrity.

Key Statistic

Approximately 130,000 people in the UK live with MS. Secondary progressive MS develops in approximately 65% of people initially diagnosed with relapsing-remitting MS. The transition typically occurs 15-20 years after diagnosis. There are currently limited disease-modifying therapies for secondary progressive MS, which drives patients toward unproven treatments.

Relevant Guidelines

• NICE CG186: Multiple sclerosis in adults — management
• MS Society guidance on unproven treatments
• GMC guidance on prescribing unlicensed medicines.

Frequently Asked Questions

How do I address social media health misinformation without being dismissive?

Start by understanding what the patient saw and why it resonated. Validate their engagement with their health: "I can see you've been actively researching, and that shows how much you care about managing your MS." Then explain the difference between anecdotal evidence and clinical evidence without condescension: "Individual stories can be very compelling, but they can't tell us whether a treatment truly works or whether what we're seeing is coincidence, placebo, or selective reporting."

Can GPs prescribe unproven treatments if the patient requests them?

GMC guidance is clear: prescribing should be evidence-based, and unlicensed or off-label medicines should only be prescribed when no suitable licensed alternative exists and the evidence supports their use. Prescribing an unproven treatment from social media would not meet this standard and could expose both the patient and the prescriber to harm. Knowing this regulatory framework demonstrates professional awareness.

What constructive alternatives can I offer an MS patient seeking unproven treatments?

Specialist neurology review (are there newer disease-modifying therapies available?), clinical trial registries (NIHR, clinicaltrials.gov — the patient may be eligible for genuine trials), MS Society resources (evidence-based information, peer support groups, helpline), psychological support for adjustment to progressive disease, and multidisciplinary rehabilitation services. Offering concrete alternatives demonstrates that you care about finding solutions, not just blocking requests.

How do I handle the emotional dimension of progressive MS in this consultation?

Acknowledge the fear directly: "I know the transition to secondary progressive MS is frightening, and I understand why you're looking for something — anything — that might change the trajectory." Validate her feelings without offering false hope. Discuss quality of life support alongside disease modification: physiotherapy, occupational therapy, MS specialist nursing, and social care planning. Showing that you care about her whole experience — not just the disease — scores highly on Relating to Others.

What is the evidence for stem cell therapy in MS?

Haematopoietic stem cell transplantation (HSCT) has genuine evidence for aggressive relapsing-remitting MS, with some studies showing sustained benefit. However, it carries significant risks (including mortality), is not available through GP prescribing, and has limited evidence in secondary progressive MS. If Janet asks specifically about HSCT, acknowledge the evidence honestly, explain the limitations, and suggest discussing eligibility with her neurologist. This demonstrates nuanced clinical knowledge.